Promising pipeline GLP agonists such as XW014, Survodutide, MK-6024, ECC5004, RGT001-075, Tirzepatide, CT 388, Pegylated exenatide, VK2735, MLX 7000 and others are under different phases of GLP agonist clinical trials
J.GeorgiouX.CooperM
Given aVNS can be implemented with minimally invasive approaches and has the potential to modulate vagal activity, there have been many early-stage clinical trials investigating a diverse range of potential therapeutic indications, including heart failure, epilepsy, depression, pre-diabetes, Parkinsons, and rheumatoid arthritis, and several aVNS devices were already developed for various applications (Verma et al
Heres how Id describe it: It dramatically quieted the food noise The constant mental chatter of what can I eat next
Anton C
studied IC/BPS patients with Hunner lesions and abnormal bladder biopsy results (including histopathologic findings of inflammatory infiltrates, granulation tissue, overexpression of mast cells, and/or intrafascicular fibrotic changes), also called ESSIC type 3C disease ( Box 35.2 ), and compared them to IC/BPS patients with normal cystoscopy and biopsy results